New Recommendations for Genetic Testing for Prostate Cancer

These recommendations come after the FDA approved two drugs – rucaparib and olaparib – that target metastatic prostate cancer in men with mutations in the BRCA genes, which have been shown to increase the risk of prostate cancer. The panel further recommended that people carrying a particular mutation (BRCA2) should begin early PSA screening as their risks of prostate cancer are much higher.

The study team emphasized that genetic testing not only allows for early diagnosis and prompt treatment of prostate cancer, but leads to a more personalized treatment on the basis of one’s genetic profile.

Read more here – https://www.jefferson.edu/about/news-and-events/2020/6/new-recommendations-on-genetic-testing-for-prostate-cancer.html